299/660 patients had low blasts (LB; BM blasts <5%) and also did not fulfill the criteria for the WHO 2022 entities MDS with low blasts and isolated 5q deletion (MDS-5q; n = 98) or MDS with biallelic TP53 inactivation (MDS-biTP53; n = 41). The gene discussed is TP53; the disease is myelodysplastic syndrome.